pyridoxamine has been researched along with Cardiovascular Stroke in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pyridoxamine was used as the antagonist of advanced glycation end products (AGEs)." | 1.42 | Advanced glycation end products induced immune maturation of dendritic cells controls heart failure through NF-κB signaling pathway. ( Cao, W; Chen, J; Chen, S; Chen, X; Chen, Y; Huang, H; Liu, P, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Evens, L | 1 |
| Beliën, H | 1 |
| D'Haese, S | 1 |
| Haesen, S | 1 |
| Verboven, M | 2 |
| Rummens, JL | 1 |
| Bronckaers, A | 1 |
| Hendrikx, M | 1 |
| Deluyker, D | 2 |
| Bito, V | 2 |
| Ferferieva, V | 1 |
| Driesen, RB | 1 |
| Lambrichts, I | 1 |
| Cao, W | 1 |
| Chen, J | 1 |
| Chen, Y | 1 |
| Chen, S | 1 |
| Chen, X | 1 |
| Huang, H | 1 |
| Liu, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Atrial Appendage Micrograft Transplantation in Conjunction With Cardiac Surgery-the AAMS2 Randomized Controlled Trial[NCT05632432] | 50 participants (Anticipated) | Interventional | 2022-12-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for pyridoxamine and Cardiovascular Stroke
| Article | Year |
|---|---|
Combinational Therapy of Cardiac Atrial Appendage Stem Cells and Pyridoxamine: The Road to Cardiac Repair?
Topics: Animals; Atrial Appendage; Combined Modality Therapy; Female; Myocardial Infarction; Pyridoxamine; R | 2021 |
Pyridoxamine improves survival and limits cardiac dysfunction after MI.
Topics: Animals; Echocardiography; Glycation End Products, Advanced; Hemodynamics; Male; Myocardial Infarcti | 2017 |
Advanced glycation end products induced immune maturation of dendritic cells controls heart failure through NF-κB signaling pathway.
Topics: Animals; Bone Marrow; Cardiotonic Agents; Cell Differentiation; Coculture Techniques; Dendritic Cell | 2015 |